Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
HKSE:06108'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.2 Med: 0.5 Max: 0.88
Current: 0.21
During the past 13 years, the highest Price to Median PS Value of New Ray Medicine International Holding was 0.88. The lowest was 0.20. And the median was 0.50.
HKSE:06108's Price-to-Median-PS-Value is ranked better than 93.96% of 265
companies
in the Healthcare Providers & Services industry
Industry Median: 0.72
vs HKSE:06108: 0.21
New Ray Medicine International Holding (HKSE:06108) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
New Ray Medicine International Holding's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.225
/
1.09
=
0.21
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
New Ray Medicine International Holding Median PS Value Related Terms
New Ray Medicine International Holding Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
New Ray Medicine International Holding Median PS Value Chart
New Ray Medicine International Holding Annual Data
New Ray Medicine International Holding Median PS Value Competitor Comparison
For the Pharmaceutical Retailers subindustry, New Ray Medicine International Holding's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
New Ray Medicine International Holding Price-to-Median-PS-Value vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, New Ray Medicine International Holding's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where New Ray Medicine International Holding's Price-to-Median-PS-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
New Ray Medicine International Holding (HKSE:06108) has a Median PS Value of HK$1.09 as of Aug. 26, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on New Ray Medicine International Holding and its competitors. According to the industry distribution chart, New Ray Medicine International Holding ranks #16 out of 265 companies in the Healthcare Providers & Services industry, placing it in the top 6%.
Is New Ray Medicine International Holding's Median PS Value too high?
New Ray Medicine International Holding's current Median PS Value is HK$1.09. Based on the distribution chart, New Ray Medicine International Holding ranks #16 out of 265 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, New Ray Medicine International Holding has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does New Ray Medicine International Holding's Median PS Value compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, New Ray Medicine International Holding ranks #16 out of 265 companies for Median PS Value. This places New Ray Medicine International Holding in the top 6% of its industry — outperforming the majority of peers. The industry median Median PS Value is 0.72. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Healthcare Providers & Services company?
The median Median PS Value among Healthcare Providers & Services companies is 0.72, based on 265 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on New Ray Medicine International Holding and its competitors. For the Healthcare Providers & Services industry, the median Median PS Value is 0.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. New Ray Medicine International Holding's current Median PS Value is HK$1.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is New Ray Medicine International Holding stock overvalued right now?
Based on GuruFocus' analysis, New Ray Medicine International Holding (HKSE:06108) is currently considered Possible Value Trap. The stock's GF Value™ is HK$1.04, compared to a current price of HK$0.23 — trading 78.4% below its estimated fair value. The current Median PS Value is HK$1.09. New Ray Medicine International Holding's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For New Ray Medicine International Holding (HKSE:06108), the current Median PS Value is HK$1.09 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is New Ray Medicine International Holding (HKSE:06108) Overvalued in 2026?
Based on GuruFocus' analysis, New Ray Medicine International Holding stock appears to be undervalued.
The current stock price of HK$0.23 is trading 78.4% below its estimated GF Value™ of HK$1.04.
GuruFocus considers New Ray Medicine International Holding to be Possible Value Trap.
Key valuation signals for HKSE:06108:
Median PS Value: HK$1.09
GF Value™: HK$1.04 vs. price of HK$0.23 (78.4% below fair value)
No single metric tells the full story. See the HKSE:06108 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
New Ray Medicine International Holding Ltd is engaged in the trading and distribution of pharmaceutical products in the People's Republic of China. The company's segments include the Distribution and trading of pharmaceutical products and the Provision of marketing and promotion services. Distribution and trading of pharmaceutical products segment consist of Injection drugs and generate maximum revenue for the company.
52GF Score
Get the complete analysis for HKSE:06108
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06108 has been successfully added to your 
